{
    "clinical_study": {
        "@rank": "127967", 
        "brief_summary": {
            "textblock": "To evaluate the safety and effectiveness of fluconazole as treatment for acute cryptococcal\n      meningitis in AIDS patients. Both newly diagnosed and relapsed patients are eligible."
        }, 
        "brief_title": "Pilot Study of Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis", 
        "condition": [
            "Meningitis, Cryptococcal", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Meningitis", 
                "Meningitis, Cryptococcal"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Antiviral therapy such as zidovudine.\n\n          -  Prophylaxis for Pneumocystis carinii pneumonia.\n\n          -  Aerosolized pentamidine.\n\n        Concurrent Treatment:\n\n        Allowed:\n\n          -  Radiation therapy for mucocutaneous Kaposi's sarcoma.\n\n        Written informed consent must be obtained for each patient, either from the patient\n        himself or from the patient's legal guardian.\n\n          -  No prior systemic antifungal therapy for cryptococcosis.\n\n          -  Success of prior therapy must have been documented by negative cerebrospinal fluid\n             (CSF) culture at the end of therapy. Following prior therapy, such patients may not\n             have received more than 1 mg/kg/wk amphotericin B in the 4 weeks before entry into\n             study.\n\n        Prior Medication:\n\n        Allowed:\n\n          -  Antiviral therapy such as zidovudine.\n\n          -  Prophylaxis for Pneumocystis carinii pneumonia.\n\n          -  Aerosolized pentamidine.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following are excluded:\n\n          -  Evidence of acute or chronic meningitis based upon any etiology other than\n             cryptococcosis.\n\n          -  History of allergy to or intolerance of imidazoles, azoles, or amphotericin B.\n\n          -  Moderate or severe liver disease defined by specified lab values.\n\n          -  Patients who are unable to take oral medication.\n\n          -  Unlikely to survive more than 2 weeks.\n\n          -  Renal impairment.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Coumarin-type anticoagulants.\n\n          -  Oral hypoglycemics.\n\n          -  Barbiturates.\n\n          -  Phenytoin.\n\n          -  Immunostimulants.\n\n          -  Investigational drugs or approved (licensed) drugs for investigational indications\n             other than aerosolized pentamidine.\n\n          -  Excluded within 4 weeks of study entry:\n\n          -  Greater than 1 mg/kg/wk amphotericin B.\n\n          -  Any exceptions to these prohibitions of concomitant medications must be approved by\n             Pfizer Central Research.\n\n        Concurrent Treatment:\n\n        Excluded:\n\n          -  Lymphocyte replacement.\n\n        Patients with the following are excluded:\n\n          -  Evidence of acute or chronic meningitis based upon any etiology other than\n             cryptococcosis.\n\n          -  History of allergy to or intolerance of imidazoles or azoles.\n\n          -  Moderate or severe liver disease defined by specified lab values.\n\n          -  Patients who are unable to take oral medication.\n\n          -  Life expectancy of < 2 weeks.\n\n          -  Any condition that may impair absorption of oral medication.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Coumarin-type anticoagulants.\n\n          -  Oral hypoglycemics.\n\n          -  Barbiturates.\n\n          -  Phenytoin.\n\n          -  Immunostimulants.\n\n          -  Investigational drugs or approved (licensed) drugs for investigational indications\n             other than aerosolized pentamidine.\n\n          -  Excluded within 4 weeks of study entry:\n\n          -  Greater than 1 mg/kg/wk amphotericin B.\n\n        Prior Treatment:\n\n        Excluded:\n\n          -  Lymphocyte replacement."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "13 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002076", 
            "org_study_id": "012J", 
            "secondary_id": "056-162"
        }, 
        "intervention": {
            "intervention_name": "Fluconazole", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Fluconazole"
        }, 
        "keyword": [
            "AIDS-Related Opportunistic Infections", 
            "Meningitis", 
            "Cryptococcosis", 
            "Fluconazole", 
            "Administration, Oral", 
            "Acquired Immunodeficiency Syndrome"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Oakland", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94609"
                    }, 
                    "name": "Summitt Med Ctr / San Francisco Gen Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10021"
                    }, 
                    "name": "Cornell Univ Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19107"
                    }, 
                    "name": "Buckley Braffman Stern Med Associates"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Pilot Study of Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002076"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 1990"
    }, 
    "geocoordinates": {
        "Buckley Braffman Stern Med Associates": "39.952 -75.164", 
        "Cornell Univ Med Ctr": "40.714 -74.006", 
        "Summitt Med Ctr / San Francisco Gen Hosp": "37.804 -122.271"
    }
}